STAAR Surgical (NASDAQ:STAA) hit a new 52-week high and low during mid-day trading on Thursday . The company traded as low as $27.90 and last traded at $27.75, with a volume of 12499 shares traded. The stock had previously closed at $27.30.
A number of equities research analysts have issued reports on STAA shares. Zacks Investment Research cut STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Friday, April 6th. BidaskClub cut STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, March 29th. William Blair raised STAAR Surgical from a “market perform” rating to an “outperform” rating in a research report on Monday, April 30th. ValuEngine raised STAAR Surgical from a “hold” rating to a “buy” rating in a research report on Saturday, May 12th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $21.00 target price on shares of STAAR Surgical in a research report on Tuesday, April 24th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.25.
The company has a debt-to-equity ratio of 0.03, a current ratio of 2.43 and a quick ratio of 1.90. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 2,720.00 and a beta of 1.21.
STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, May 2nd. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. STAAR Surgical had a return on equity of 6.80% and a net margin of 0.66%. The company had revenue of $27.09 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the prior year, the business earned ($0.05) earnings per share. equities analysts anticipate that STAAR Surgical will post 0.03 EPS for the current fiscal year.
In other news, CFO Deborah J. Andrews sold 13,331 shares of the stock in a transaction that occurred on Thursday, May 3rd. The stock was sold at an average price of $17.60, for a total value of $234,625.60. Following the completion of the sale, the chief financial officer now directly owns 28,998 shares of the company’s stock, valued at $510,364.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Keith Holliday sold 2,188 shares of the stock in a transaction that occurred on Thursday, March 22nd. The shares were sold at an average price of $16.03, for a total value of $35,073.64. Following the completion of the sale, the chief technology officer now directly owns 43,781 shares of the company’s stock, valued at $701,809.43. The disclosure for this sale can be found here. Insiders sold 26,810 shares of company stock valued at $451,186 over the last three months. 3.90% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Palo Alto Investors LP boosted its position in shares of STAAR Surgical by 0.5% in the first quarter. Palo Alto Investors LP now owns 3,515,385 shares of the medical instruments supplier’s stock valued at $52,028,000 after acquiring an additional 18,633 shares during the period. Millrace Asset Group Inc. boosted its position in shares of STAAR Surgical by 24.4% in the first quarter. Millrace Asset Group Inc. now owns 128,861 shares of the medical instruments supplier’s stock valued at $1,908,000 after acquiring an additional 25,290 shares during the period. Element Capital Management LLC bought a new stake in shares of STAAR Surgical in the first quarter valued at approximately $156,000. Next Century Growth Investors LLC bought a new stake in shares of STAAR Surgical in the first quarter valued at approximately $1,852,000. Finally, GSA Capital Partners LLP boosted its position in shares of STAAR Surgical by 28.1% in the first quarter. GSA Capital Partners LLP now owns 29,480 shares of the medical instruments supplier’s stock valued at $436,000 after acquiring an additional 6,459 shares during the period. 78.92% of the stock is owned by institutional investors.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.